Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia

Investigational New Drugs

Volumn 26, Issue 2, 2008, Pages 139-149

  Jensen, Markus ^a   Engert, Andreas ^a   Weissinger, Florian ^b   Knauf, Wolfgang ^c   Kimby, Eva ^d   Poynton, Christopher ^e   Oliff, Ira Anton ^f   Rummel, Mathias J ^g   Österborg, Anders ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c Bethanien Krankenhaus Frankfurt   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f Midwest Cancer Research Group   (United States)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antileukemic activity; CLL; NSAID; R etodolac; Safety

Indexed keywords

ETODOLAC;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; B CELL LEUKEMIA; BACKACHE; BILIRUBIN URINE LEVEL; BLOOD TOXICITY; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENANTIOMER; ERYTHEMA; FACE PAIN; FATIGUE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPESTHESIA; HYPOURICEMIA; KIDNEY DISEASE; LIMB PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; LOOSE FECES; LYMPH NODE PAIN; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; OCCULT BLOOD; PAIN; PERIPHERAL SWELLING; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SKIN TOXICITY; SPLENOMEGALY; THROMBOCYTOPENIA; THRUSH; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETODOLAC; FEMALE; HALF-LIFE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 40549091701     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9106-z     Document Type: Article

References (33)

1. Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057
2. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-815
3. Robertson TI (1990) Complications and causes of death in B cell chronic lymphocytic leukaemia: a long term study of 105 patients. Aust N Z J Med 20:44-50
4. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559-566
5. Zent CS, Kay NE (2004) Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2:107-113
6. Rai KR, Peterson BL, Appelbaum FR Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757
7. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700
8. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M (2006) A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106:337-345
9. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ (2003) Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 153-175
10. Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J (1998) Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92:1406-1414
11. Klampfer L, Cammenga J, Wisniewski HG, Nimer SD (1999) Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 93:2386-2394
12. Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190:445-450
13. Pereg D, Lishner M (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258:115-123
14. Brocks DR, Jamali F (1990) The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. Drug Metab Dispos 18:471-475
15. Brocks DR, Jamali F (1994) Etodolac clinical pharmacokinetics. Clin Pharmacokinet 26:259-274
16. Demerson CA, Humber LG, Abraham NA, Schilling G, Martel RR, Pace-Asciak C (1983) Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 26:1778-1780
17. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI (1992) Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 327:749-754
18. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J (2002) Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 25:537-544
19. Nardella FA, LeFevre JA (2002) Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood 99:2625-2626
20. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB (2004) Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell 5:565-574
21. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA, Zhang XK (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A 102:2525-2530
22. Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, Shinjo K, Naito K, Ohnishi K (2005) Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol 75:212-220
23. Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC (2005) SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106:706-712
24. Nakamura S, Kobayashi M, Shibata K, Sahara N, Shigeno K, Shinjo K, Naito K, Hayashi H, Ohnishi K (2006) Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res 30:123-135
25. Adachi S, Leoni LM, Carson DA, Nakahata T (2004) Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol 111:107-123
26. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101:3118-3123
27. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997
28. Drazen JM (2005) COX-2 inhibitors-a lesson in unexpected problems. N Eng J Med 352:1131-1132
29. Robak T (2006) New agents in chronic lymphocytic leukemia. Curr Treat Options Oncol 7:200-212
30. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23:7024-7031
31. Wierda WG, Kipps TJ, Keating MJ (2005) Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23:6325-6332
32. Lindhagen E, Rickardson L, Elliott G, Leoni L, Nygren P, Larsson R, Åleskog A (2007) Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro. Invest New Drugs 25:297-303
33. Lindhagen E, Nissle S, Leoni L, Elliott G, Chao Q, Larsson R, Åleskog A (2006) R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol 60:545-553